GENE Stock - Genetic Technologies Limited
Unlock GoAI Insights for GENE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.66M | $10.35M | $6.79M | $120,554 | $837,865 |
| Gross Profit | $3.90M | $6.01M | $6.47M | $-240,473 | $736,432 |
| Gross Margin | 50.9% | 58.1% | 95.3% | -199.5% | 87.9% |
| Operating Income | $-12,210,212 | $-10,416,411 | $-7,544,048 | $-7,421,561 | $-5,938,503 |
| Net Income | $-12,017,219 | $-11,750,923 | $-7,130,998 | $-7,077,619 | $-6,294,775 |
| Net Margin | -156.8% | -113.6% | -104.9% | -5870.9% | -751.3% |
| EPS | $-2.73 | $-3.60 | $-2.32 | $-2.48 | $-4.50 |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Visit WebsiteEarnings History & Surprises
GENEEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Jul 29, 2025 | — | — | — | — |
Q2 2025 | May 27, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Oct 2, 2024 | — | — | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.03 | — | — |
Q2 2024 | Apr 29, 2024 | — | — | — | — |
Q1 2024 | Mar 19, 2024 | — | $-1.09 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-1.30 | — | — |
Q1 2023 | Feb 23, 2023 | — | $-0.78 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-1.16 | — | — |
Q3 2022 | Aug 30, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.73 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.92 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.00 | — | — |
Q3 2021 | Aug 30, 2021 | — | $-0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.91 | — | — |
Q1 2021 | Feb 26, 2021 | — | — | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.98 | — | — |
Q3 2020 | Aug 30, 2020 | — | — | — | — |
Q2 2020 | Jun 30, 2020 | — | $-1.40 | — | — |
Latest News
Frequently Asked Questions about GENE
What is GENE's current stock price?
What is the analyst price target for GENE?
What sector is Genetic Technologies Limited in?
What is GENE's market cap?
Does GENE pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GENE for comparison